# US 2015/0105431 A1 · Nicotine Lozenge Composition

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0105431 A1
- Document ID: US20150105431A1
- Status: Published application
- Kind: A1
- Application number: 14/572,953
- Filed: 2014-12-17
- Published: 2015-04-16
- Earliest claimed: 2008-05-01
- Assignees: GlaxoSmithKline LLC
- Applicants: GlaxoSmithKline, LLC
- Inventors: Li-Lan CHEN
- Web page: https://patentgrep.com/patent/US20150105431A1

## CPC

- A61K 31/465: Nicotine; Derivatives thereof
- A61K 9/0056: {Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals}
- A61K 9/16: Agglomerates; Granulates; Microbeadlets {; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction (A61K9/20 takes precedence if the final form is a tablet; microspheres with drug-free outer coating, microcapsules A61K9/50; mixture of different granules, microcapsules, (coated) microparticles A61K9/5084; nanoparticles A61K9/51)}
- A61K 9/2009: {Inorganic compounds}
- A61K 9/2018: {Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates}
- A61K 9/2027: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61K 9/205: {Polysaccharides, e.g. alginate, gums; Cyclodextrin}
- A61K 9/2095: {Tabletting processes}
- A61K 31/715: Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61P 25/30: for treating abuse or dependence
- A61P 25/34: Tobacco-abuse
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to nicotine lozenge compositions comprising reduced levels of buffering agents from traditional nicotine lozenges and which provide optimal oral pH and prompt nicotine absorption in a smaller, more convenient dosage form.

## Claims

### Claim 1

An oral lozenge composition comprising:
a) a master granule component comprising: at least one an alkaline buffering agent; at least one dissolution modifier; and at least one filler;
b) a nicotine active; and
c) at least one alkaline buffering agent.

### Claim 2 (depends on 1)

The oral lozenge composition of claim 1 wherein the master granules are obtained through wet or dry granulation.

### Claim 3 (depends on 1)

The oral lozenge composition of claim 1 wherein the at least one dissolution modifier is selected from the group consisting of acacia, agar, alginic acid or a salt thereof, carbomer, carboxymethylcellulose, carrageenan, cellulose, chitosan, copovidone, cyclodextrins, ethylcellulose, gelatin, guar gum, hydroxyethyl cellulose, hydroxyethyl methylcellulose, hydroxypropyl cellulose, hypromellose, inulin, methylcellulose, pectin, polycarbophil or a salt thereof, polyethylene glycol, polyethylene oxide, polyvinyl alcohol, pullulan, starch, tragacanth, trehalose, xanthan gum and mixtures thereof.

### Claim 4 (depends on 3)

The oral lozenge composition of claim 3 wherein the at least one dissolution modifier is selected from the group consisting of alginic acid or a salt thereof, polycarbophil or a salt thereof, xanthan gum and mixtures thereof.

### Claim 5 (depends on 4)

The oral lozenge composition of claim 4 wherein the at least one dissolution modifier is selected from the group consisting of sodium alginate, calcium polycarbophil, xanthan gum and mixtures thereof.

### Claim 6 (depends on 5)

The oral lozenge composition of claim 5 wherein the at least one dissolution modifier is xanthan gum.

### Claim 7 (depends on 1)

The oral lozenge of claim 1 wherein the nicotine active is nicotine polacrilex.

### Claim 8 (depends on 1)

The oral lozenge of claim 1 wherein the filler is mannitol.

### Claim 9 (depends on 1)

The oral lozenge of claim 1 wherein the alkaline buffering agents are selected from the group consisting of sodium carbonate, sodium bicarbonate, potassium phosphate, potassium carbonate and potassium bicarbonate, and mixtures thereof.

### Claim 10 (depends on 1)

The oral lozenge of claim 1 further comprising at least one optional excipient selected from the group consisting of taste masking agents, sweetening agents, flavorants, chelating agents, antioxidants, glidants or colorants.

### Claim 11 (depends on 1)

The oral lozenge of claim 1 wherein the unit weight of the oral lozenge is from about 100 mg to about 500 mg.

### Claim 12 (depends on 11)

The oral lozenge of claim 11 wherein the oral lozenge dissolves in less than 15 minutes upon administration to the oral cavity.

### Claim 13

A nicotine containing lozenge composition with improved user compliance prepared by the process of:
a) granulating at least one alkaline buffering agent, at least one dissolution modifier and at least one filler into a master granulation,
b) mixing said master granulation with a nicotine active and an alkaline buffering agent; and
c) directly compressing said mixture into oral lozenge dosage forms.

### Claim 14 (depends on 13)

The nicotine containing lozenge composition with improved user compliance prepared by the process of claim 13 wherein the unit weight of the oral lozenge dosage form is from about 100 mg to about 500 mg.

### Claim 15 (depends on 14)

The nicotine containing lozenge composition with improved user compliance prepared by the process of claim 14 wherein the unit weight of the oral lozenge dosage form is about 250 mg.

### Claim 16 (depends on 14)

The nicotine containing lozenge composition with improved user compliance prepared by the process of claim 14 wherein the oral lozenge dosage form dissolves in less than 15 minutes upon administration to the oral cavity.

### Claim 17 (depends on 12)

The nicotine containing lozenge composition with improved user compliance prepared by the process of claim 12 further comprising at least one optional excipient selected from the group consisting of taste masking agents, sweetening agents, flavorants, chelating agents, antioxidants, glidants or colorants.

### Claim 18

A nicotine containing lozenge composition which provides increased maximum pH in the oral cavity and fast nicotine absorption prepared by the process of:
a) granulating at least one alkaline buffering agent, at least one dissolution modifier and at least one filler into a master granulation,
b) mixing said master granulation with a nicotine active and an alkaline buffering agent; and
c) directly compressing said mixture into an oral lozenge formulation.
